Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Raderer

Showing results (251-260 of 264) with videos related to

Pageof 27
Sort By:
Heart (British Cardiac Society)|September 30, 2015
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortalityNoemi Pavo, Markus Raderer, Martin Hülsmann, et al.
Infectious Agents and Cancer|February 14, 2023
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trialMaximilian J Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, et al.
Cancers|July 2, 2021
Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue LymphomaBarbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 15, 2019
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerationsMarius E Mayerhoefer, Helmut Prosch, Lucian Beer, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Oncotarget|November 9, 2017
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patientsNoemi Pavo, Markus Raderer, Georg Goliasch, et al.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Haematologica|February 25, 2021
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemiaChristoph Kornauth, Charles Herbaux, Bernd Boidol, et al.
Cancer Medicine|March 22, 2022
The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignanciesAlexander Gaiger, Simone Lubowitzki, Katharina Krammer, et al.
Leukemia|May 22, 2021
Thyroid MALT lymphoma: self-harm to gain potential T-cell helpFangtian Wu, Natsuko Watanabe, Maria-Myrsini Tzioni, et al.
Pageof 27

Showing results (251-260 of 264) with videos related to

Sort By:
Pageof 27
Heart (British Cardiac Society)|September 30, 2015
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortalityNoemi Pavo, Markus Raderer, Martin Hülsmann, et al.
Infectious Agents and Cancer|February 14, 2023
Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trialMaximilian J Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Pröll, et al.
Cancers|July 2, 2021
Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue LymphomaBarbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 15, 2019
PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerationsMarius E Mayerhoefer, Helmut Prosch, Lucian Beer, et al.
BJC Reports|November 8, 2024
Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialMarta Ligero, Jorge Hernando, Eric Delgado, et al.
Oncotarget|November 9, 2017
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patientsNoemi Pavo, Markus Raderer, Georg Goliasch, et al.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Haematologica|February 25, 2021
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemiaChristoph Kornauth, Charles Herbaux, Bernd Boidol, et al.
Cancer Medicine|March 22, 2022
The cancer survival index-A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignanciesAlexander Gaiger, Simone Lubowitzki, Katharina Krammer, et al.
Leukemia|May 22, 2021
Thyroid MALT lymphoma: self-harm to gain potential T-cell helpFangtian Wu, Natsuko Watanabe, Maria-Myrsini Tzioni, et al.
Pageof 27